Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > No deals

<< Previous

Bullboard Posts

Next >>

Comment by RalphRalphon Jun 28, 2021 11:12am

153 Views

Post# 33459604

RE:No deals

If you're implying that there is no interest from Big Pharma, do you believe that Nuance erred in its diligence? Hard to believe that Mark Lotter would be the only BP exec to see value in the company.

If you're implying that a deal is not likely to finalize anytime soon, I agree with you.

Doccole wrote: If there was deals on the table the ceo wouldn't be selling shares like he did a few weeks ago.

remeber the dates of the amalgamation - when the hold comes up. I am sure there will be a pump followed by insider dump. This is going based on Hx here. I am guessing the beginning of the phase 3 will be similar.

this is opportunity to buy more, but it's risky. Money maybe stuck here for years.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China